Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 12/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427699 | 0.78 | LPL (0.37) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL20480347 | 0.75 | PIK3CG (0.47) | LPLLIPGPIK3CGFFAR1CA1 | |
| SCHEMBL18057173 | 0.75 | LPL (0.40) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL14658714 | 0.75 | LPL (0.40) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL27035810 | 0.75 | FFAR1 (0.41) | DYRK1ALPLLIPGFFAR1 | |
| SCHEMBL218127 | 0.74 | LPL (0.39) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL24718096 | 0.73 | L3MBTL1 (0.50) | LPLLIPGFFAR1 | |
| SCHEMBL31647070 | 0.73 | L3MBTL1 (0.33) | MEN1CYP1A2KMT2ADYRK1AKEAP1 | |
| SCHEMBL1820427 | 0.72 | LPL (0.40) | DYRK1ALPLLIPGTGFBR1FFAR1 | |
| SCHEMBL20600818 | 0.71 | LPL (0.39) | LPLLIPGTGFBR1FFAR1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735114-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2026-05-06 | — | — | EP | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4661964-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-4617265-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-3126362-A1 | ANTI-FIBROTIC PYRIDINONES | Intermune, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015153683-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-2303886-A2 | PI3K/M TOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MEN1 822/4885CYP1A2 2007/4885KMT2A 2302/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | MEN1 3710/4885CYP1A2 2296/4885KMT2A 3907/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | MEN1 3914/4885CYP1A2 152/4885KMT2A 3085/4885 |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | MEN1 4126/4885CYP1A2 2319/4885KMT2A 3982/4885 |
| US-20160257690-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | MEN1 2068/4885CYP1A2 3145/4885KMT2A 2516/4885 |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | CCR6, CCR4, CCR1 | MEN1 2758/4885CYP1A2 1959/4885KMT2A 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.